Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
As an alternative to invasive tissue biopsies for the determination of EGFR-mutation status
Selection of patients with non-small cell lung cancer who are most likely to benefit from targeted therapies
This test evaluates cell-free DNA (cfDNA) in the peripheral blood for the presence of common EGFR mutations in exons 18, 19, 20, and 21 in patients with non-small cell lung cancer and can be used to assess eligibility for targeted therapies. Current data suggests that the efficacy of EGFR-targeted therapy in non-small cell lung cancer patients is limited to patients whose tumors harbor mutations in the EGFR gene.
This test is not validated for serial monitoring of patients with cancer. This test is also not intended as a screening test to identify cancer.
Quantitative Polymerase Chain Reaction (PCR) Analysis